Related references
Note: Only part of the references are listed.Targeted nuclear medicine. Seek and destroy
Vladimir M. Tolmachev et al.
RUSSIAN CHEMICAL REVIEWS (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Richard D. Baird et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
Tianqi Xu et al.
CANCERS (2021)
Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(R) Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain
Yongsheng Liu et al.
PHARMACEUTICS (2021)
From thiol-subtilisin to omniligase: Design and structure of a broadly applicable peptide ligase
Ana Toplak et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life
Fabian Brandl et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules
Javad Garousi et al.
MOLECULES (2020)
Radiopharmaceutical therapy in cancer: clinical advances and challenges
George Sgouros et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond
Javad Garousi et al.
EJNMMI RADIOPHARMACY AND CHEMISTRY (2020)
Efficient Enzymatic Cyclization of Disulfide-Rich Peptides by Using Peptide Ligases
Marcel Schmidt et al.
CHEMBIOCHEM (2019)
Sustainable, cost-efficient manufacturing of therapeutic peptides using chemo-enzymatic peptide synthesis (CEPS)
Jan Pawlas et al.
GREEN CHEMISTRY (2019)
Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab
Anna Orlova et al.
MOLECULAR PHARMACEUTICS (2018)
Affibody Molecules in Biotechnological and Medical Applications
Stefan Stahl et al.
TRENDS IN BIOTECHNOLOGY (2017)
Peptiligase, an Enzyme for Efficient Chemoenzymatic Peptide Synthesis and Cyclization in Water
Ana Toplak et al.
ADVANCED SYNTHESIS & CATALYSIS (2016)
Improved solid phase synthesis of peptide carboxyamidomethyl (Cam) esters for enzymatic segment condensation
Timo Nuijens et al.
TETRAHEDRON LETTERS (2016)
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Jens Sorensen et al.
THERANOSTICS (2016)
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
Matthias D'Huyvetter et al.
THERANOSTICS (2014)
Deciphering complex protein interaction kinetics using Interaction Map
Daniele Altschuh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition
Vladimir Tolmachev et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
Christel Larbouret et al.
NEOPLASIA (2012)
Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
J. Lofblom et al.
FEBS LETTERS (2010)
Design of an Optimized Scaffold for Affibody Molecules
Joachim Feldwisch et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific affibody molecule
Vladimir Tolmachev et al.
CANCER RESEARCH (2007)
Automated, high-resolution cellular retention and uptake studies in vitro
Henrik Bjorke et al.
APPLIED RADIATION AND ISOTOPES (2006)
Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis
A Wunder et al.
JOURNAL OF IMMUNOLOGY (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
